Navigation Links
Medicsight PLC Receives Additional Information Request for FDA 510(k) Clearance
Date:1/26/2010

NEW YORK, Jan. 26 /PRNewswire-FirstCall/ -- Medicsight PLC, a subsidiary of MGT Capital Investments, Inc. (NYSE Amex: MGT), and an industry leader in the development of Computer-Aided Detection (CAD) and image analysis software which assists radiologists in the early detection of disease, announces that on January 5, 2010 it received a further request for Additional Information (AI) letter from the US Food and Drug Administration (FDA) relating to the Company's currently pending 510(k) pre-market notification for the ColonCAD API 3.1 product.

The FDA previously issued an AI letter to the Company in December, 2008 requesting clarification of the intended use of the product, to which the Company responded. In the most recent AI letter the FDA has requested further technical details regarding the clinical trials and data analyses undertaken to support clearance of the product.

FDA 510(k) submissions for Class 2 devices such as the current ColonCAD API 3.1 submission are necessarily complex and require the sponsor company to provide a great deal of information relating to the design, manufacture and validation of the product. It is not unusual for a second AI request to be received by a company in order for the FDA to gain all the information they require in order to assess a device. However, the FDA's 510(k) process is typically restricted to two AI letters.

Allan Rowley, CEO of Medicsight, said: "We are working expediently with our clinical and statistical advisors and the FDA to prepare the requested information and expect to respond fully to the FDA before the deadline of June 21, 2010."

About MGT Capital Investments, Inc.

MGT Capital Investments, Inc. is a technology holding company that focuses on investments in the global healthcare information technology market. The Company has two subsidiaries, Medicsight PLC and Medicexchange PLC.

Medicsight PLC (AIM: MDST) is a UK-headquartered, research driven, leading developer of computer-aided detection (CAD) and image analysis software for the medical imaging market. The CAD software automatically highlights suspicious areas on computerized tomography (CT) scans of the colon and lung, helping radiologists to identify, measure and analyze potential disease and early indicators of disease. Medicsight's CAD software has been validated using one of the world's largest and most population diverse databases of verified patient CT scan data. Medicsight's ColonCAD(TM) and LungCAD(TM) software products are seamlessly integrated with the advanced 3D visualization workstations of several industry-leading imaging equipment partners.

Medicexchange PLC provides medical imaging professionals with a global web portal containing an online sales, jobs and information channel for diagnostic, treatment and surgery planning solutions. This combined with a variety of relevant clinical papers, training materials and content gives these professionals access to information and products that they otherwise would have difficulty accessing.

Additional information can be found at www.mgtci.com.

All forward-looking statements are made pursuant to the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current management expectations that involve risks and uncertainties that may result in such expectations not being realized. Potential risks and uncertainties include, but are not limited to, the risks described in company filings with the Securities and Exchange Commission.

SOURCE MGT Capital Investments, Inc.; Medicsight PLC

RELATED LINKS
http://www.mgtci.com

'/>"/>

SOURCE MGT Capital Investments, Inc.; Medicsight PLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ACRIN Study Endorses Virtual Colonoscopy - Validation for Colon CAD Software Maker Medicsight plc
2. Novo Nordisks Victoza(R) Receives FDA Approval for Adults With Type 2 Diabetes
3. KV Pharmaceutical Receives Report From Inspector of Elections Certifying Votes to Approve Appointment of Director
4. Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease
5. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Ofloxacin and Fleroxacin
6. GeneGo Receives SBIR Grant
7. WorldHeart Receives Unconditional BTT Study Approval From FDA for Levacor(TM) VAD
8. VIA Pharmaceuticals Receives Delisting Notification From NASDAQ
9. KV Pharmaceutical Receives Permission from NYSE for its Securities to Continue Trading on the NYSE until March 31, 2010
10. AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Gram-Negative Bloodstream Pathogens
11. Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories New Drug Application (NDA) for Efavirenz Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)...  Infinity Pharmaceuticals, Inc. (NASDAQ: INFI ) ... th Annual Healthcare Conference on Monday, March 6, ... MA. A live webcast of Infinity,s presentation ... website at www.infi.com , and will be available ... Infinity,Infinity is an innovative biopharmaceutical company dedicated to advancing ...
(Date:2/27/2017)... Inc. (NASDAQ: IPXL ) today announced that it plans to ... Raymond James and Associates, 38 th Annual Institutional Investors Conference ... FL. Cowen and Company 37 th ... in Boston, MA. Barclays Global ... Miami, FL. Individuals may listen to ...
(Date:2/27/2017)... -- A recent research report published by Grand View ... expected to reach a value of $55.8 billion by 2025. Earlier ... states have legalized marijuana for medical uses. In 2016, states such ... North Dakota , Ohio ... drug in medical applications such as chemotherapies and pain management. The ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... February 27, 2017 , ... This webinar , sponsored ... a tool to characterize particle size distributions in the field of geoscience and ... novel scientific findings. It describes methods of optimized and standardized sample collection, preparation ...
(Date:2/27/2017)... ... February 27, 2017 , ... POUGHKEEPSIE, N. Y. – Peer-reviewed guidelines from ... scientific studies, the Center for Disease Control ( CDC ) and Infectious Diseases Society ... B. Liegner, M.D. has compiled into a single volume a compelling argument that the ...
(Date:2/27/2017)... ... February 27, 2017 , ... Sunshine Coast Health Centre ... Columbia, Canada, at https://www.sunshinecoasthealthcentre.ca/ , is proud to announce the addition of ... showcases the Centre's commitment to innovation in drug rehab and alcohol treatment strategies ...
(Date:2/27/2017)... ... February 27, 2017 , ... ... and environs, is proud to announce an upgrade to the company's Yelp listing. ... Yelp page on topics as diverse as Platelet Rich Plasma (PRP) therapy, hair ...
(Date:2/26/2017)... , ... February 25, 2017 , ... The February 13, ... heightened awareness and concern over nerve agents and the deadly use of chemical weapons. ... nervous system and how even small doses can be lethal. , Jay Jagannathan, M.D., ...
Breaking Medicine News(10 mins):